This is of particular interest because KEAP-1 mutant NSCLC cells, such as A549, are particularly aggressive and exhibit therapy resistance as patients with tumors harboring this mutational profile appear to have worse clinical outcomes (42–44). Here, KEAP1 is linked to non-small cell lung carcinoma.